Pekka Taimen profile picture
Professor, Institute of Biomedicine
InFLAMES Flagship


+358 29 450 4524
+358 50 431 1353
Kiinamyllynkatu 10

Areas of expertise

cell biology
prostate cancer, bladder cancer, cardiomyopathy, nuclear lamin


Pekka Taimen received his MD degree from the University of Turku in 2001 and defended his thesis at the Department of Pathology, University of Turku in 2004. In 2008-2009 PT worked as a postdoctoral fellow in the laboratory of Prof. Robert D. Goldman, Northwestern University Medical School, Chicago. Postdoctoral studies focusing on nuclear intermediate filament proteins called lamins were further continued as a junior group leader after returning back to Turku in early 2010. In 2011 PT received a specialist degree in Pathology and since then he has worked as a part-time specialist at the Pathology Division, Turku University Hospital with special focus on uropathology. From 2012 PT has worked as a Clinical lecturer in Pathology and between 2015-2019 as a part-time Academy of Finland Clinical Researcher. PT was appointed as a tenure track Assistant Professor of Molecular Pathology in January 2019 and an Associate Professor in August 2020. In January 2022, PT was appointed as a Professor of Molecular Pathology and he currently serves as the head of the pathology unit at the Faculty of Medicine, University of Turku.


Pekka Taimen has more than 10 years of experience in teaching medical students at the Institute of Biomedicine, University of Turku. He has served first as a university teacher and from 2012 as a clinical lecturer. In 2015 PT received the Lecturer of the Year award in the Faculty of Medicine.


Professor Pekka Taimen has 20 years of experience in cell and molecular biology as well as in translational research. The main focus of his research group is on human diseases caused by lamin mutations, such as cardiomyopathies and premature aging syndrome. More recently, PT has also actively worked on prostate and bladder cancer related projects including novel biomarkers, biobanking, patient derived cell lines and improved imaging techniques utilizing digital pathology and machine learning approaches.


Sort by:

The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource (2022)

Cancer Epidemiology, Biomarkers and Prevention
Ouellet V., Erickson Andrew on behalf of GAP1 UTMAs Contributing Investigators, Wiley K., Morrissey C., Berge V., Moreno C.S., Tasken K.A., Trudel D., True L.D., Lewis M.S., Svindland A., Ertunc O., Vidal I.D., Osunkoya A.O., Jones T., Steven Bova G., Lamminen Tarja, Achtman A.H., Buzza M., Kouspou M.M., Bigler S.A., Zhou X., Freedland S.J., Mes-Masson A.M., Garraway I.P., Trock B.J., Taimen Pekka, Saad F., Mirtti T., Knudsen B.S., De Marzo A.M.
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

PP2A methylesterase PME-1 suppresses anoikis and is associated with therapy relapse of PTEN-deficient prostate cancers (2022)

Molecular Oncology
Aakula Anna, Isomursu Aleksi, Rupp Christian, Erickson Andrew, Gupta Nikhil, Kauko Otto, Shah Pragya, Padzik Artur, Pokharel Yuba Raj, Kaur Amanpreet, Li Song-Ping, Trotman Lloyd, Taimen Pekka, Rannikko Antti, Lammerding Jan, Paatero Ilkka, Mirtti Tuomas, Ivaska Johanna, Westermarck Jukka
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Increased Expression and Altered Cellular Localization of Fibroblast Growth Factor Receptor-Like 1 (FGFRL1) Are Associated with Prostate Cancer Progression (2022)

Yu Lan, Toriseva Mervi, Afshan Syeda, Cangiano Mario, Fey Vidal, Erickson Andrew, Seikkula Heikki, Alanen Kalle, Taimen Pekka, Ettala Otto, Nurmi Martti, Boström Peter J, Kallajoki Markku, Tuomela Johanna, Mirtti Tuomas, Beumer Inès J, Nees Matthias, Härkönen Pirkko
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Individualised non-contrast MRI-based risk estimation and shared decision-making in men with a suspicion of prostate cancer: protocol for multicentre randomised controlled trial (multi-IMPROD V.2.0) (2022)

BMJ Open
Ettala Otto, Jambor Ivan, Perez Ileana Montoya, Seppänen Marjo, Kaipia Antti, Seikkula Heikki, Syvänen Kari T, Taimen Pekka, Verho Janne, Steiner Aida, Saunavaara Jani, Saukko Ekaterina, Löyttyniemi Eliisa, Sjoberg Daniel D, Vickers Andrew, Aronen Hannu, Boström Peter
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))